FindTrial
Sign In

Stereotactic biopsy

PROCEDURE5 trials

Sponsors

Dana-Farber Cancer Institute, University Hospital Muenster, Mayo Clinic, Hospital San Carlos, Madrid, Jonsson Comprehensive Cancer Center

Conditions

Anaplastic Oligodendroglioma of Brain (Diagnosis)AstrocytomaBrain CancerBrain TumorCancer BrainEpendymomaGangliogliomaGlioblastoma

Phase 1

A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
Active, not recruitingNCT03152318
Dana-Farber Cancer InstituteAnaplastic Oligodendroglioma of Brain (Diagnosis), Astrocytoma, Brain Cancer +11
Start: 2017-07-18End: 2028-01-01Target: 62Updated: 2026-03-04
Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial
RecruitingNCT05030298
Mayo ClinicMalignant Glioma
Start: 2023-05-23End: 2027-09-15Target: 28Updated: 2025-11-21
Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma
RecruitingNCT06418113
Hospital San Carlos, MadridCancer Brain, Glioblastoma, Glioblastoma, IDH-wildtype +2
Start: 2024-03-21End: 2027-03-21Target: 12Updated: 2024-05-16
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RecruitingNCT06650163
Jonsson Comprehensive Cancer CenterGlioma, Malignant Brain Neoplasm, Meningioma +1
Start: 2024-12-05End: 2028-01-31Target: 20Updated: 2026-02-05

Phase 2

Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma
TerminatedNCT04469699
University Hospital MuensterGlioblastoma Multiforme, Adult
Start: 2021-04-12End: 2025-01-30Updated: 2025-03-11

Related Papers

Abstract 7743: Pre-existing T cells drive durable anti-tumor immunity after oncolytic virus therapy in glioblastoma
Cancer Research2026-04-03
Abstract 7774: Blockade of cell-ECM interaction with an oncolytic virus suppresses tumoral STING activation while inducing antitumor immunity
Cancer Research2026-04-03
IMMU-10. HSV-1–Mediated Species-Specific Fc-Dependent Antibody Internalization: A Model to Investigate Preexisting Immunity in Glioblastoma Oncolytic Virotherapy
Neuro-Oncology2025-11-01
CTIM-35. MULTI-OMIC AND SINGLE CELL ASSESSMENT OF SERIAL BIOPSIES REVEALS RESPONSES TO CAN-3110 ONCOLYTIC IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA THAT ARE NOT EVIDENT BY ROUTINE CLINICAL ANALYSES
Neuro-Oncology2025-11-01
1047 Preoperative Stereotactic Radiosurgery Positively Modulates the Tumor Immune Microenvironment in Glioblastoma: Preliminary Findings of a Phase I/IIa Human Clinical Trial
Neurosurgery2025-03-14
Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy
Neuro-Oncology2024-06-1015 citations
Longitudinal stereotactic injections of oncolytic immunoactivating rQNestin34.5v.2 (CAN-3110) with concomitant biopsies for “-omic” analyses in recurrent glioblastoma (GBM).
Journal of Clinical Oncology2024-06-011 citations
ALA-RDT in GBM: protocol of the phase I/II dose escalation trial of radiodynamic therapy with 5-Aminolevulinic acid in patients with recurrent glioblastoma
Radiation Oncology2024-01-2217 citations
EXTH-70. UTILIZING ONCOLYTIC VIROTHERAPY AS AN APPROACH TO ENHANCE NEOANTIGEN SPECIFIC IMMUNE RESPONSES IN GLIOBLASTOMA
Neuro-Oncology2023-11-01
CTIM-41. ONCOLYTIC IMMUNOTHERAPY LINKS IMMUNOACTIVATION TO SUBJECT SURVIVAL IN PHASE I TRIAL OF RECURRENT GLIOBLASTOMA
Neuro-Oncology2023-11-01
Clinical trial links oncolytic immunoactivation to survival in glioblastoma.
2023-10-18175 citations
Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: Translational developments from rodents to glioma patients.
2023-08-1214 citations
Assessment of The Impact of Oncolytic Virotherapy on The Immunopeptidome Profile of Tumor by Utilizing GEMM Derived Immunocompetent GBM Models
The Journal of Immunology2023-05-011 citations
896 Oncolytic herpes simplex virus immuno-virotherapy in combination with tigit immune checkpoint blockade to treat glioblastoma
Regular and Young Investigator Award Abstracts2022-11-01
Abstract 6388: The effect of oncolytic virus therapy on neoantigen specific immune responses
Cancer Research2022-06-15
NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy
Clinical Cancer Research2022-01-1150 citations
IM-4 Impact of oHSV activated NOTCH signaling in tumor microenvironment and its impact on anti-tumor immunity
Neuro-Oncology Advances2021-12-01
EXTH-61. MODULATION OF THE IL-27 RECEPTOR SIGNALING PATHWAY IN GLIOBLASTOMA AND ONCOLYTIC VIROTHERAPY
Neuro-Oncology2021-11-021 citations
First-in-human CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma.
Journal of Clinical Oncology2021-05-207 citations
Preclinical Toxicology of rQNestin34.5v.2: An Oncolytic Herpes Virus with Transcriptional Regulation of the ICP34.5 Neurovirulence Gene.
2020-03-3072 citations